May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
A Randomized Controlled Trial Evaluating the Efficacy of Neurovision's Neural Vision CorrectionTM Technology in Enhancing Unaided Visual Acuity in Adults With Low Myopia
Author Affiliations & Notes
  • M. Jamil
    Singapore Eye Research Institute, Singapore, Singapore
  • A. Fong
    Singapore Eye Research Institute, Singapore, Singapore
  • D. Tan
    Singapore Eye Research Institute, Singapore, Singapore
  • Footnotes
    Commercial Relationships  M. Jamil, None; A. Fong, None; D. Tan, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1436. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Jamil, A. Fong, D. Tan; A Randomized Controlled Trial Evaluating the Efficacy of Neurovision's Neural Vision CorrectionTM Technology in Enhancing Unaided Visual Acuity in Adults With Low Myopia. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1436.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy of NeuroVision’s Neural Vision CorrectionTM (NVCTM) Technology in enhancing unaided visual acuity in adults with low myopia.

Methods: : NeuroVision’s NVCTM technology is a non-invasive, patient-specific, perceptual learning program based on visual stimulation and facilitation of neural connections at the cortical level. It involves an internet-based computer generated visual training exercise regime using stimuli based on Gabor patches, to sharpen contrast sensitivity and visual acuity. A double masked randomized controlled trial was conducted to evaluate the efficacy of NVCTM technology in improving unaided visual acuity (UAVA) of low myopic patients. 84 adult low myopic patients (LMP) with SE ≤ -1.5D (mean SE -1.29D) were randomly divided into 2 groups. Group A (66 LMP) completed NVCTM treatment, Group B (18 LMP) completed sham treatment.

Results: : Mean UAVA improved by 0.186 logMar in Group A compared to 0.023 logMar in Group B. 65.2% of LMP in group A improved more than 0.2 logMar in at least one eye compared to 11.1% in Group B (p<0.0005). Mean refractive error remained unchanged.

Conclusions: : NVCTM treatment demonstrated statistically significant UAVA improvement in adults with low myopia.

Clinical Trial: : www.clinicaltrials.gov NCT00348075

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • myopia • visual acuity 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×